(2016) identified a PDE1 inhibitor clinical candidate, Compound 1 (ITI-214) , via systematic pyrazolo-pyrimidinone scaffold optimizations
A further important safety concern is the unknown interaction profile of these peptides with prescribed medications, including insulin, antihypertensives, and hormonal therapies
PROteolysis TArgeting Chimera (PROTAC)
These registers contain comprehensive health information on the entire population, enabling a detailed examination of medication use patterns
At the same time, the Phase III results werent quite as impressive as Novo Nordisk appeared to be expecting (25% or greater weight loss), and it will face stiff market competition from Eli Lillys existing drug tirzepatide, which has provided slightly lower but similar results in clinical trials